The stock is now up 1.4 percent on the BSE.
Glenmark Pharmaceuticals is trading on a firm note on the BSE in early morning session, after the company received ANDA approval.
According to a release issued by the company to the BSE, Glenmark Pharma today reported that is has been granted final approval by the United States Food & Drug Administration (USFDA) for the extended-cycle oral contraceptive, Levonorgestrel/Ethinyl Estradiol Tablets USP. 015 mg/0.03 mg.
Now, the stock is trading near the highest level of the day at Rs. 894 - with a gain of 1.4 percent at Rs. 892.
So far, the counter has witnessed trades of around 20,000 shares as compared to its two-week daily average volume of 77,000 shares.
Meanwhile, the BSE Sensex has jumped 157 points at 26,582.
According to a release issued by the company to the BSE, Glenmark Pharma today reported that is has been granted final approval by the United States Food & Drug Administration (USFDA) for the extended-cycle oral contraceptive, Levonorgestrel/Ethinyl Estradiol Tablets USP. 015 mg/0.03 mg.
Now, the stock is trading near the highest level of the day at Rs. 894 - with a gain of 1.4 percent at Rs. 892.
So far, the counter has witnessed trades of around 20,000 shares as compared to its two-week daily average volume of 77,000 shares.
Meanwhile, the BSE Sensex has jumped 157 points at 26,582.
No comments:
Post a Comment